HUNTINGTON BEACH, Calif., Sept. 12 /PRNewswire/ -- WayPoint Biomedical Holdings, Inc. (Pink Sheets: WYPH) has signed a multi-year lease with First Huntington Capital, L.P. for additional office space to accommodate the growth of WayPoint's expanding operations. WayPoint Biomedical will relocate their corporate headquarters to the 12th Floor of the Plaza Huntington Beach building, Suite 1200. WayPoint CEO, Dennis Shepherd, comments, "We are delighted to have additional space available that can accommodate WayPoint's expansion and professional growth." According to building Property Manager, Rhonda Lauer, "On behalf of building Ownership, we are pleased to present this Lease Document, which will relocate WayPoint's current office into Suite 1200." About WayPoint Biomedical: WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (Pink Sheets: WYPH), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, wellness, fitness and environment. The Company develops and markets a unique array of cutting-edge products, which includes their Health Essist(R) Hangover-Free Topical Patch for the Convenience Store market and their OTC approved Health Essist Drugs-of-Abuse product range. WayPoint's tests offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. The Company's primary target sectors are the Over the Counter (OTC) Wellness & Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security & Defense Market; three of the fastest growing areas in all of diagnostic medicine and science. For more information on WayPoint Biomedical visit http://www.waypointbiomedical.com/ , http://www.drinkdetectiveusa.com/ . Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law. Dennis Shepherd, 714-848-3200 E-mail: Investor Relations: The Steven Fox Group Steven Fox, 831-333-1452 E-mail: DATASOURCE: WayPoint Biomedical, Inc. CONTACT: Dennis Shepherd of WayPoint Biomedical, Inc., +1-714-848-3200, ; or Investor Relations, Steven Fox of The Steven Fox Group, +1-831-333-1452, , for WayPoint Biomedical, Inc. Web site: http://www.drinkdetectiveusa.com/ Web site: http://www.waypointbiomedical.com/

Copyright